In early July Henry Ford Hospital reported some positive results treating COVID-19 with hydroxychloroquine even after every credible research laboratory declared it to be ineffective.
https://mtskeptics.blogspot.com/2020/07/hydroxychloroquine-cut-covid-death-rate.html
So what's the story?
Like masks, hydroxychloroquine became associated with political affiliation. Trump hyped it at White House briefings, and even announced that he himself was taking it. The FDA revoked its use. Nevertheless, White House trade adviser Peter Navarro is still pointing to the Henry Ford study, But it was a retrospective one, neither randomized nor controlled. “The Detroit study touted by Navarro has very poor methodology—completely observational, meaning that the choice to give hydroxychloroquine was probably also linked to other factors that explain the benefit,” says Bob Wachter, chair of the department of medicine at UC San Francisco.
https://mtskeptics.blogspot.com/2020/07/hydroxychloroquine-cut-covid-death-rate.html
So what's the story?
Like masks, hydroxychloroquine became associated with political affiliation. Trump hyped it at White House briefings, and even announced that he himself was taking it. The FDA revoked its use. Nevertheless, White House trade adviser Peter Navarro is still pointing to the Henry Ford study, But it was a retrospective one, neither randomized nor controlled. “The Detroit study touted by Navarro has very poor methodology—completely observational, meaning that the choice to give hydroxychloroquine was probably also linked to other factors that explain the benefit,” says Bob Wachter, chair of the department of medicine at UC San Francisco.
"What is the cost of continuing these trials?”
The politics and social alignments that swirled around hydroxychloroquine made it hard for US researchers to enroll enough participants to make a study work. That slowed things down. An analysis by Stat showed that of the more than 1,200 Covid-19 drug trials underway or planned, 237,000 people—more than a third of volunteers in all the trials—were supposed to be enrolled in hydroxychloroquine studies. That now seems disproportionate, to say the least. “Nobody should get it,”
The politics and social alignments that swirled around hydroxychloroquine made it hard for US researchers to enroll enough participants to make a study work. That slowed things down. An analysis by Stat showed that of the more than 1,200 Covid-19 drug trials underway or planned, 237,000 people—more than a third of volunteers in all the trials—were supposed to be enrolled in hydroxychloroquine studies. That now seems disproportionate, to say the least. “Nobody should get it,”
Wachter says. “Overall, the evidence against it is strong enough that the drug should simply go away in Covid, and it would have weeks ago had it not been for the politics.”
No comments:
Post a Comment